Drug Delivery Systems Market Synopsis

Global Drug Delivery Systems Market Size Was Valued at USD 39.55 Billion In 2022 And Is Projected to Reach USD 78.76 Billion By 2030, Growing at A CAGR of 9.1% From 2023 To 2030.

The process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals is known as drug delivery. The first generation (1950–1980) produced a large number of oral and transdermal controlled release formulations for clinical applications. In the recent research and development (R & D) sector, scientific and technical developments are ready for the expansion of oral drug delivery systems.

• The Drug Delivery Systems market has witnessed significant growth and innovation, driven by the increasing demand for targeted and controlled drug delivery in healthcare. These systems enhance the therapeutic efficacy of drugs while minimizing side effects, leading to improved patient outcomes. Key drivers include the rising prevalence of chronic diseases, technological advancements, and the need for personalized medicine.
• Nanotechnology plays a pivotal role in drug delivery, enabling the development of nanoparticles and liposomes for precise drug targeting. Additionally, sustained-release formulations, implantable devices, and transdermal patches contribute to the market's expansion. Biopharmaceutical companies are investing in research and development to create novel drug delivery solutions, fostering collaborations and partnerships.
• Geographically, North America and Europe dominate the market due to advanced healthcare infrastructure and substantial investments in research. However, Asia-Pacific is emerging as a key player, driven by increasing healthcare expenditure and a growing patient population.

Drug Delivery Systems Market Trend Analysis

A rise in The Prevalence of Chronic Diseases

• Chronic diseases increase in the world due to, the rising aging population, as well as changes in societal behavior, which are all contributing to a steady rise in these common and costly long-term health issues. People are becoming more sedentary as the middle class expands and urbanization accelerates leading to an increase in the use of tobacco and exposure to second-hand smoke. Poor nutrition, including diets low in fruits and vegetables and high in sodium and saturated fats. Physical Inactivity. It tends to rise the cases of chronic diseases. Obesity rates and cases of diseases such as diabetes are rising as a result.
• According to the World Health Organization, the prevalence of chronic diseases was 57% in 2020. Emerging markets will be hardest hit, as population growth is expected to be greatest in developing countries. The increased demand on healthcare systems as a result of chronic disease has become a major source of concern. The growing prevalence of chronic diseases is supposed to drive the growth of the drug delivery system market in the forecast period.

Lucrative Opportunity in the Growing Production of Novel Drugs

• The drug delivery system market is expected to healthy growth in the coming years, owing to the advances in the drug delivery system gaining attention and popularity as a result of the use of Nano formulations, which enable efficient, effective, and specific drug targeting. Liposomes, aptamers, quantum dots, peptides, polymers, metals, and magnetic nanoparticle-based delivery are examples of advanced-generation drug delivery systems.
• The structural complexity of Nano-based drug delivery systems, such as dendrimers, Nano sponges, nanocrystals, nanogels, and Nanocapsules, provides a large surface area for precise targeting in cancer management and other life-threatening diseases. The growing production of novel drugs and their dosage form tends to be a lucrative opportunity for the market of drug delivery systems in the upcoming year.

Drug Delivery Systems Market Segment Analysis:

Drug Delivery Systems Market Segmented on the basis of type, application, and Technology.

By Type, oral drug delivery segment is expected to dominate the market during the forecast period

• The oral drug delivery segment is forecasted to dominate the drug delivery system market in the upcoming future. The Oral drug delivery system is commonly used for the administration of the drug. It is the most preferred route and most well-known route of drug administration because it is easy to use, non-invasive in nature, cost-effective, and has high absorption properties in the gastrointestinal tract.
• It is suitable for frequent and extended use. It is cost-effective because the patient incurs no additional expenses. Where the drug is a solid, such as a tablet or capsule, the patient only needs one or two cups of water, which is usually readily available. If the drug is in liquid form, all that is required is a measuring tool, which is usually included with the drug. Thus, the oral drug delivery segment is expected to grow significantly during the forecast period due to the aforementioned factors.

By Technology, targeted drug delivery segment held the largest share of 45% in 2022

• The targeted drug delivery system segment is expected to dominate the drug delivery system market in the upcoming year. The targeted drug delivery system is a novel drug delivery system, drugs are directly delivered to the targeted body area. It is also called a smart drug delivery system. The targeted drug delivery systems have several advantages over conventional drug delivery such as low side effects, improvement of pharmaceutical activity, and reduction of the administered dose.
• The primary goal of a targeted drug delivery system is to direct the therapeutic agent's pharmacological action only to diseased organs while leaving healthy organs alone, particularly in the case of cancer treatment with chemotherapeutic agents. Thus, the drug delivery system segment is expected to grow significantly during the forecast period due to the aforementioned factors.

Drug Delivery Systems Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America is anticipated to have the highest share of the drug delivery system market in the forecast period due to the increased adoption rate of new technological advancements in the drug delivery system. The United States is a prominent country in the North American region. During the forecast period, the US drug delivery systems market is expected to grow at the fastest rate.
• The increasing prevalence of chronic diseases and the growing number of products launched by key players, and the increasing use of drug delivery systems for disease management are driving the growth of this market. Strong demand for drug delivery systems is expected to drive the drug delivery systems market growth in North America during the forecast period, owing to an increase in hospital admissions in the region.
• According to a CIHI article published in April 2021, there were more than 3 million acute inpatient hospitalizations in Canada in 2019–2020. These hospitalizations are expected to increase the region's demand for drug delivery systems.

Drug Delivery Systems Market Top Key Players:

• 3M Company (US)
• Abbott Laboratories (US)
• Baxter International Inc. (US)
• Zimmer Biomet Holdings, Inc. (US)
• Cook Medical (US)
• Eli Lilly and Company (US)
• BD (Becton, Dickinson and Company) (US)
• Merck & Co., Inc. (US)
• Pfizer Inc. (US)
• Stryker Corporation (US)
• Johnson & Johnson (US)
• Sanofi (France)
• Bayer AG (Germany)
• Boehringer Ingelheim GmbH (Germany)
• Medtronic plc (Ireland)
• Alkermes plc (Ireland)
• AstraZeneca plc (UK)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Roche Holding AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Terumo Corporation (Japan)
• Samsung Medison Co., Ltd. (South Korea)

Key Industry Developments in the Drug Delivery Systems Market:

• In June 2023, Johnson & Johnson announced a collaboration with Accenture to develop and implement a blockchain-based platform for tracking and verifying the authenticity of pharmaceuticals, aiming to combat counterfeiting.
• In October 2023, Johnson & Johnson Janssen unit launched Stelara (ustekinumab) as the first subcutaneous biologic treatment for moderate-to-severe plaque psoriasis in adults, offering a more convenient and patient-preferred administration method.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. DRUG DELIVERY SYSTEMS MARKET BY TYPE (2016-2030)
   1. DRUG DELIVERY SYSTEMS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. INJECTION-BASED DRUG DELIVERY SYSTEM
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. ORAL DRUG DELIVERY SYSTEM
   5. INHALATION/PULMONARY DRUG DELIVERY SYSTEM
   6. TRANSMUCOSAL DRUG DELIVERY SYSTEM
7. DRUG DELIVERY SYSTEMS MARKET BY APPLICATION (2016-2030)
   1. DRUG DELIVERY SYSTEMS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. ONCOLOGY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. CARDIOVASCULAR DISEASES
   5. UROLOGY
8. DRUG DELIVERY SYSTEMS MARKET BY TECHNOLOGY (2016-2030)
   1. DRUG DELIVERY SYSTEMS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. PRODRUG
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. IMPLANTS
   5. INTRAUTERINE DEVICES
   6. TARGETED DRUG DELIVERY
   7. POLYMERIC DRUG DELIVERY
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. DRUG DELIVERY SYSTEMS Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. 3M COMPANY (US)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. ABBOTT LABORATORIES (US)
   4. BAXTER INTERNATIONAL INC. (US)
   5. ZIMMER BIOMET HOLDINGS, INC. (US)
   6. COOK MEDICAL (US)
   7. ELI LILLY AND COMPANY (US)
   8. BD (BECTON, DICKINSON AND COMPANY) (US)
   9. MERCK & CO., INC. (US)
   10. PFIZER INC. (US)
   11. STRYKER CORPORATION (US)
   12. JOHNSON & JOHNSON (US)
   13. SANOFI (FRANCE)
   14. BAYER AG (GERMANY)
   15. BOEHRINGER INGELHEIM GMBH (GERMANY)
   16. MEDTRONIC PLC (IRELAND)
   17. ALKERMES PLC (IRELAND)
   18. ASTRAZENECA PLC (UK)
   19. VNOVARTIS AG (SWITZERLAND)
   20. F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
   21. ROCHE HOLDING AG (SWITZERLAND)
   22. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
   23. TERUMO CORPORATION (JAPAN)
   24. SAMSUNG MEDISON CO., LTD. (SOUTH KOREA)
10. GLOBAL DRUG DELIVERY SYSTEMS MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Type
       4. Historic And Forecasted Market Size By Application
       5. Historic And Forecasted Market Size By Technology
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. DRUG DELIVERY SYSTEMS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. DRUG DELIVERY SYSTEMS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. DRUG DELIVERY SYSTEMS MARKET COMPETITIVE RIVALRY
TABLE 005. DRUG DELIVERY SYSTEMS MARKET THREAT OF NEW ENTRANTS
TABLE 006. DRUG DELIVERY SYSTEMS MARKET THREAT OF SUBSTITUTES
TABLE 007. DRUG DELIVERY SYSTEMS MARKET BY TYPE
TABLE 008. INJECTION-BASED DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
TABLE 009. ORAL DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
TABLE 010. INHALATION/PULMONARY DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
TABLE 011. TRANSMUCOSAL DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
TABLE 012. OTHER MARKET OVERVIEW (2016-2028)
TABLE 013. DRUG DELIVERY SYSTEMS MARKET BY APPLICATION
TABLE 014. ONCOLOGY MARKET OVERVIEW (2016-2028)
TABLE 015. CARDIOVASCULAR DISEASES MARKET OVERVIEW (2016-2028)
TABLE 016. UROLOGY MARKET OVERVIEW (2016-2028)
TABLE 017. OTHER MARKET OVERVIEW (2016-2028)
TABLE 018. DRUG DELIVERY SYSTEMS MARKET BY TECHNOLOGY
TABLE 019. PRODRUG MARKET OVERVIEW (2016-2028)
TABLE 020. IMPLANTS & INTRAUTERINE DEVICES MARKET OVERVIEW (2016-2028)
TABLE 021. TARGETED DRUG DELIVERY MARKET OVERVIEW (2016-2028)
TABLE 022. POLYMERIC DRUG DELIVERY MARKET OVERVIEW (2016-2028)
TABLE 023. OTHER MARKET OVERVIEW (2016-2028)
TABLE 024. NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET, BY TYPE (2016-2028)
TABLE 025. NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION (2016-2028)
TABLE 026. NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET, BY TECHNOLOGY (2016-2028)
TABLE 027. N DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY (2016-2028)
TABLE 028. EUROPE DRUG DELIVERY SYSTEMS MARKET, BY TYPE (2016-2028)
TABLE 029. EUROPE DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION (2016-2028)
TABLE 030. EUROPE DRUG DELIVERY SYSTEMS MARKET, BY TECHNOLOGY (2016-2028)
TABLE 031. DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY (2016-2028)
TABLE 032. ASIA PACIFIC DRUG DELIVERY SYSTEMS MARKET, BY TYPE (2016-2028)
TABLE 033. ASIA PACIFIC DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION (2016-2028)
TABLE 034. ASIA PACIFIC DRUG DELIVERY SYSTEMS MARKET, BY TECHNOLOGY (2016-2028)
TABLE 035. DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA DRUG DELIVERY SYSTEMS MARKET, BY TYPE (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION (2016-2028)
TABLE 038. MIDDLE EAST & AFRICA DRUG DELIVERY SYSTEMS MARKET, BY TECHNOLOGY (2016-2028)
TABLE 039. DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY (2016-2028)
TABLE 040. SOUTH AMERICA DRUG DELIVERY SYSTEMS MARKET, BY TYPE (2016-2028)
TABLE 041. SOUTH AMERICA DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION (2016-2028)
TABLE 042. SOUTH AMERICA DRUG DELIVERY SYSTEMS MARKET, BY TECHNOLOGY (2016-2028)
TABLE 043. DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY (2016-2028)
TABLE 044. GERRESHEIMER AG: SNAPSHOT
TABLE 045. GERRESHEIMER AG: BUSINESS PERFORMANCE
TABLE 046. GERRESHEIMER AG: PRODUCT PORTFOLIO
TABLE 047. GERRESHEIMER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. BD (BECTON: SNAPSHOT
TABLE 048. BD (BECTON: BUSINESS PERFORMANCE
TABLE 049. BD (BECTON: PRODUCT PORTFOLIO
TABLE 050. BD (BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. DICKINSON: SNAPSHOT
TABLE 051. DICKINSON: BUSINESS PERFORMANCE
TABLE 052. DICKINSON: PRODUCT PORTFOLIO
TABLE 053. DICKINSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. AND COMPANY): SNAPSHOT
TABLE 054. AND COMPANY): BUSINESS PERFORMANCE
TABLE 055. AND COMPANY): PRODUCT PORTFOLIO
TABLE 056. AND COMPANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. KINDEVA DRUG DELIVERY: SNAPSHOT
TABLE 057. KINDEVA DRUG DELIVERY: BUSINESS PERFORMANCE
TABLE 058. KINDEVA DRUG DELIVERY: PRODUCT PORTFOLIO
TABLE 059. KINDEVA DRUG DELIVERY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. BAXTER: SNAPSHOT
TABLE 060. BAXTER: BUSINESS PERFORMANCE
TABLE 061. BAXTER: PRODUCT PORTFOLIO
TABLE 062. BAXTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. WEST PHARMACEUTICAL SERVICES INC.: SNAPSHOT
TABLE 063. WEST PHARMACEUTICAL SERVICES INC.: BUSINESS PERFORMANCE
TABLE 064. WEST PHARMACEUTICAL SERVICES INC.: PRODUCT PORTFOLIO
TABLE 065. WEST PHARMACEUTICAL SERVICES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. YPSOMED: SNAPSHOT
TABLE 066. YPSOMED: BUSINESS PERFORMANCE
TABLE 067. YPSOMED: PRODUCT PORTFOLIO
TABLE 068. YPSOMED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. MEDTRONIC: SNAPSHOT
TABLE 069. MEDTRONIC: BUSINESS PERFORMANCE
TABLE 070. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 071. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. NEMARA: SNAPSHOT
TABLE 072. NEMARA: BUSINESS PERFORMANCE
TABLE 073. NEMARA: PRODUCT PORTFOLIO
TABLE 074. NEMARA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. E3D ELCAM DRUG DELIVERY DEVICES: SNAPSHOT
TABLE 075. E3D ELCAM DRUG DELIVERY DEVICES: BUSINESS PERFORMANCE
TABLE 076. E3D ELCAM DRUG DELIVERY DEVICES: PRODUCT PORTFOLIO
TABLE 077. E3D ELCAM DRUG DELIVERY DEVICES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. PFIZER INC.: SNAPSHOT
TABLE 078. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 079. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 080. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. 3M: SNAPSHOT
TABLE 081. 3M: BUSINESS PERFORMANCE
TABLE 082. 3M: PRODUCT PORTFOLIO
TABLE 083. 3M: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 084. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 085. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 086. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY TYPE
FIGURE 012. INJECTION-BASED DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
FIGURE 013. ORAL DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
FIGURE 014. INHALATION/PULMONARY DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
FIGURE 015. TRANSMUCOSAL DRUG DELIVERY SYSTEM MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 017. DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY APPLICATION
FIGURE 018. ONCOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 019. CARDIOVASCULAR DISEASES MARKET OVERVIEW (2016-2028)
FIGURE 020. UROLOGY MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 022. DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY TECHNOLOGY
FIGURE 023. PRODRUG MARKET OVERVIEW (2016-2028)
FIGURE 024. IMPLANTS & INTRAUTERINE DEVICES MARKET OVERVIEW (2016-2028)
FIGURE 025. TARGETED DRUG DELIVERY MARKET OVERVIEW (2016-2028)
FIGURE 026. POLYMERIC DRUG DELIVERY MARKET OVERVIEW (2016-2028)
FIGURE 027. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 028. NORTH AMERICA DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. EUROPE DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. ASIA PACIFIC DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. MIDDLE EAST & AFRICA DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. SOUTH AMERICA DRUG DELIVERY SYSTEMS MARKET OVERVIEW BY COUNTRY (2016-2028)